Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JAMES G SULLIVAN

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1588613020
CMS profile
207840
Location
BIRMINGHAM, AL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$2,465.21

143 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,340.65 131
Education $124.56 12

By paying entity

PY2023 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 143 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JAMES G SULLIVAN

NPI 1588613020 · CMS profile ID 207840

Allopathic & Osteopathic Physicians / Internal Medicine

BIRMINGHAM, AL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 143 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1588613020?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JAMES G SULLIVAN, NPI 1588613020, CMS profile ID 207840. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 143 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1588613020?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). JAMES G SULLIVAN, NPI 1588613020, CMS profile ID 207840. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 143 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1588613020?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
JAMES G SULLIVAN, NPI 1588613020, CMS profile ID 207840, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 143 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1588613020?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

143 matching records · $2,465.21 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 143 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 143.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novo Nordisk Inc $18.7607/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000295075 CMS
Esperion Therapeutics, Inc. $21.3307/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050747701 CMS
PFIZER INC. $12.1407/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049176649 CMS
GlaxoSmithKline, LLC. $25.8006/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001799019 CMS
AbbVie Inc. $4.3306/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999163751 CMS
Novo Nordisk Inc $16.6906/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000295003 CMS
Mycovia Pharmaceuticals, Inc. $22.7406/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1030685717 CMS
PFIZER INC. $2.0806/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049534689 CMS
Lilly USA, LLC $18.3306/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031600195 CMS
Novo Nordisk Inc $20.8906/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000295091 CMS
Novo Nordisk Inc $14.7906/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000294977 CMS
AbbVie Inc. $3.5806/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999163747 CMS
GlaxoSmithKline, LLC. $3.0806/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001798535 CMS
Teva Pharmaceuticals USA, Inc. $17.7006/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056813559 CMS
Otsuka America Pharmaceutical, Inc. $29.8005/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014852185 CMS
GlaxoSmithKline, LLC. $27.9605/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001799325 CMS
Amgen Inc. $23.3305/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020593015 CMS
Ardelyx, Inc. $20.9505/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1052963483 CMS
Novo Nordisk Inc $18.3305/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000295050 CMS
Exact Sciences Corporation $19.1605/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1026622695 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $10.3805/10/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996819833 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $10.3805/10/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996819835 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $10.3805/10/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996819839 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $10.3805/10/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996819841 CMS
AbbVie Inc. $3.3005/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999163743 CMS
Lilly USA, LLC $18.1505/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031700131 CMS
Novo Nordisk Inc $18.8305/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000295085 CMS
Lilly USA, LLC $19.6104/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031600185 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $13.1304/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057492609 CMS
AbbVie Inc. $4.4304/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999163739 CMS
PFIZER INC. $19.6504/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050671591 CMS
Lundbeck LLC $28.2204/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032376317 CMS
Novo Nordisk Inc $18.3304/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000295045 CMS
AbbVie Inc. $13.4104/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999163735 CMS
ITI, Inc. $29.0604/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040715573 CMS
Lilly USA, LLC $22.6704/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031600179 CMS
GlaxoSmithKline, LLC. $26.3204/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001798515 CMS
PFIZER INC. $22.3604/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050380867 CMS
Lilly USA, LLC $14.2904/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031700125 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $10.3804/07/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996819827 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $10.3804/07/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996819829 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $10.3804/07/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996819847 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $10.3804/07/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996819851 CMS
PFIZER INC. $4.4204/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050657239 CMS
AbbVie Inc. $12.9604/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999163729 CMS
AbbVie Inc. $2.2404/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999163727 CMS
Exact Sciences Corporation $19.7604/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1026622653 CMS
Novo Nordisk Inc $0.5904/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000294969 CMS
Novo Nordisk Inc $15.3904/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000294981 CMS
AstraZeneca Pharmaceuticals LP $24.3503/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011924523 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $16,097.89 170
PY2020 $2,567.35 175
PY2021 $2,929.85 183
PY2022 $3,259.95 176
PY2023 $2,465.21 143
PY2024 $2,800.69 140
PY2025 $8,950.43 131

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $595,410.59 10
PY2024 Principal investigator $793,452.21 9
PY2023 Recipient $12,184.22 3
PY2023 Principal investigator $1,099,612.87 9
PY2022 Recipient $34,456.20 2
PY2022 Principal investigator $1,721,896.62 5
PY2021 Recipient $4,178.03 2
PY2021 Principal investigator $1,737,255.10 3
PY2020 Principal investigator $15,900.00 1
PY2019 Principal investigator $16,096.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

10 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Novartis Pharmaceuticals Corporation $764.50 12/12/2025 Non-covered Recipient Entity
PARKWAY MEDICAL CENTER
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Atherosclerotic Cardiovascular Disease (ASCVD), and Elevated LDL-C No dispute reported 06/30/2026 1190313849
Principal investigator 1 Novartis Pharmaceuticals Corporation $6,109.24 10/30/2025 Non-covered Recipient Entity
PARKWAY MEDICAL CENTER
A multi-center, randomized, double-blind, placebo-controlled, parallel-group, dose-finding study to evaluate efficacy, safety, and tolerability of DII235 in adults with elevated lipoprotein(a) No dispute reported 06/30/2026 1190306907
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,695.55 06/16/2025 Non-covered Recipient Entity
PARKWAY MEDICAL CENTER
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open-Label Pelacarsen in Participants With Elevated Lp(a) and Established ASCVD No dispute reported 06/30/2026 1190306911
Principal investigator 1 Eli Lilly and Company $204,696.00 02/18/2025 Non-covered Recipient Entity
JAMES G SULLIVAN DBA PARKWAY MEDICAL CTR
A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE No dispute reported 06/30/2026 1187881642
Principal investigator 1 Eli Lilly and Company $7,720.99 01/27/2025 Non-covered Recipient Entity
LIGHTSHIP INC
A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE No dispute reported 06/30/2026 1187884580
Principal investigator 1 Eli Lilly and Company $164,031.00 01/21/2025 Non-covered Recipient Entity
LIGHTSHIP INC
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187884156
Principal investigator 1 AstraZeneca UK Limited $54,406.00 01/13/2025 Non-covered Recipient Entity
PARKWAY MEDICAL CENTER
A Phase I-III Randomized Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156-AZD3152 for Pre exposure Prophylaxis of COVID 19 in Participants with Conditions Causing Immune Impairment No dispute reported 06/30/2026 1185539601
Principal investigator 1 Eli Lilly and Company $1,972.20 01/09/2025 Non-covered Recipient Entity
LIGHTSHIP INC
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187886382
Principal investigator 1 Novartis Pharmaceuticals Corporation $154,000.11 01/08/2025 Non-covered Recipient Entity
PARKWAY MEDICAL CENTER
A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a) and established atherosclerotic cardi No dispute reported 06/30/2026 1190306909
Principal investigator 1 Novartis Pharmaceuticals Corporation $15.00 01/01/2025 Non-covered Recipient Entity
PARKWAY MEDICAL CENTER
A Multi-center, Randomized, Double-blind, Parallel-group, 20-week Dose-finding Study to Evaluate Efficacy, Safety, and Tolerability of XXB750 in Patients With Resistant Hypertension No dispute reported 06/30/2026 1190306913